Search Within

Joachim Yahalom

  1. "GSK Faculty"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (20)
  3. Book Section (2)
  4. Conference Paper (2)
  5. Research Letter (1)
Groups
  1. GSK Faculty (53)
  2. Radiation Oncology, Department of (53)
  3. Survivorship Research (53)
  4. Department of Medicine (41)
  5. Hematologic Malignancies, Division of (38)
  6. Center for Hematologic Malignancies (34)

More Groups

People
  1. Maria Palomba (18)
  2. Andrew Zelenetz (15)
  3. Santosha Vardhana (15)
  4. Alison Moskowitz (14)
  5. Zvi Fuks (14)
  6. Ahmet Dogan (13)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (7)
  4. 2022 (2)
  5. 2021 (4)
  6. 2020 (3)

More Years

Publications
  1. Blood (17)
  2. Journal of Clinical Oncology (5)
  3. Hematological Oncology (4)
  4. International Journal of Radiation Oncology, Biology, Physics (4)
  5. Proceedings of the American Association for Cancer Research Annual Meeting (3)
  6. Biology of Blood and Marrow Transplantation (2)

More Publications

Publishers
  1. American Society of Hematology (18)
  2. Elsevier Inc. (8)
  3. American Association for Cancer Research (5)
  4. American Society of Clinical Oncology (5)
  5. Wiley Blackwell (5)
  6. Nature Publishing Group (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genetic Alterations of CREBBP are associated with radiosensitivity in follicular lymphoma
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E. S.; Lee, J.; Fregonese, B.; Tringale, K. R.; Hubbeling, H.; Sarkar, R.; Ma, J.; Seshan, V.; Joffe, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pathogenic ATM mutations in cancer and a genetic basis for radiotherapeutic efficacy
    Journal Article

    Pitter, K. L.; Casey, D. L.; Lu, Y. C.; Hannum, M.; Zhang, Z.; Song, X.; Pecorari, I.; McMillan, B.; Ma, J.; Samstein, R. M.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy
    Journal Article

    Imber, B. S.; Sadelain, M.; DeSelm, C.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Giralt, S.; Park, J. H.; Sauter, C.; Scordo, M.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save